Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNABased Lead Candidate CDR132L in Heart Failure Patients PostMyocardial Infarction

Cardior Announces First Patient Dosed…

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Cardior Raises €64 M Series…